Corindus to Feature CorPath® GRX System at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions

WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today that it will be participating in the SCAI 2017 Scientific Sessions to be held May 10-13 in New Orleans, LA. Robotic-assisted percutaneous coronary intervention (PCI) will be featured throughout the conference, including in the exhibit hall, presentations, and during a lunch symposium.

SCAI attendees are invited to register for the educational lunch symposium entitled "The Next Generation of Cath Lab Robotics" sponsored by Corindus on Friday, May 12 from 12:15 - 1:15pm. The symposium, chaired by Ehtisham Mahmud, MD, FSCAI of UC San Diego School of Medicine, will also feature faculty and key robotic physicians Ryan Madder, MD, Frederick Meijer Heart & Vascular Institute, Spectrum Health, and Paul Campbell, MD, Carolinas HealthCare System NorthEast. Audience Q&A and discussion will follow the symposium presentations. 

Symposium Chairman Ehtisham Mahmud, MD, stated, "I look forward to sharing how robotic PCI can be incorporated to the contemporary practice of interventional cardiology. Recent advancements in the CorPath technology platform have been transformational and I am enthusiastic about the future of robotics in the treatment of complex coronary disease."

The symposium will feature the following topics: 

• "The Field of Vascular Robotics" with Ehtisham Mahmud, MD 
• "Building a Robotic Program: My First 100 Cases" with Ryan Madder, MD 
• "Robotic Precision" with Paul Campbell, MD 
• "Robotics First: Capabilities of Robotics in Complex Intervention Cases" with Ehtisham Mahmud, MD

Space for the lunch symposium is limited; registration is available at www.corindus.com/SCAI2017. 

During the conference, Dr. Mahmud will also present study data from the PRECISION Registry as a Late Breaking Clinical Trial.

In addition to educational opportunities to learn more about robotics, the CorPath GRX System will be on display in Corindus' Booth 304. To schedule a hands-on demonstration of robotic-assisted PCI with an advanced simulator, please visit www.corindus.com/SCAI2017. 

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath^® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc. 

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. An example of such a statement is about the future of robotics in treatment of complex artery disease.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.

Contacts

Corindus Vascular Robotics, Inc.
Media Contact:
Kate Stanton, 508-653-3335 ext. 200
kate.stanton@corindus.com
or
Investor Contact:
Lynn Pieper Lewis, 415-937-5402
ir@corindus.com